Reuters reported on Monday that shares of GW Pharmaceuticals (NASDAQ:GWPH) more than doubled in value on Monday after the company released promising test results for an experimental marijuana drug.
As quoted in the publication:
Following positive results in the first Phase 3 study of its investigational medicine Epidiolex, GW Pharma’s stock popped by 139 percent intraday. While GW Pharma grows marijuana, it only extracts a non psychoactive component of the plant called CBD.
The experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial. Analysts, on average, believe the drug could generate annual sales of $1.1 billion by 2021, according to consensus forecasts compiled by Thomson Reuters Cortellis.
Click here for the full Reuters article.
table.inline-text-ad {
border-left: none;
border-right: none;
}
.inline-text-ad h1 {
font-size: 18px !important;
font-weight: bold !important;
}
.inline-text-ad p {
font-size: 1.0rem;
}
Get the Top Stories on Resource Investing FREE!
Learn what is going on before you buy from this FREE Special Report, Who is Kitco? to US Mint: Sold Out! – Top Articles from Resource Investing News.
The post Shares of GW Pharmaceuticals Skyrocket on Successful Cannabis Drug Trial appeared first on Investing News Network.
To continue reading this story, visit our friend’s website (opens in a new window):: Shares of GW Pharmaceuticals Skyrocket on Successful Cannabis Drug Trial